水飞蓟宾治疗脂肪肝的疗效观察

Observation on the therapeutic efficacy of silibinin capsules for patients with fatty liver disease

目的探讨水飞蓟宾胶囊治疗脂肪肝的疗效。方法采用开放、随机、对照试验将58例脂肪肝患者随机分为治疗组33例和对照组25例,分别给予口服水飞蓟宾胶囊70mg,3次/日和多烯磷脂酰胆碱胶囊456mg,3次/日,根据治疗前后临床症状、血清酶学、血脂及腹部CT的变化,评价治疗的疗效和安全性。结果治疗组与对照组治疗后血清酶学、血脂较治疗前明显下降(P<0.05),治疗组TG的下降较对照组明显(P<0.05);治疗后经CT检查显示两组脂肪肝的程度均较治疗前有明显的改善。未发现明显的副作用。结论水飞蓟宾胶囊治疗脂肪肝与多烯磷脂酰胆碱胶囊同样具有良好的疗效及安全性,不仅使血清酶学下降,还可降低血脂,改善肝内脂肪沉积。

Objectives To observe the clinical efficacy and safety of silibinin capsules on fatty liver disease（FL）. Methods An open,randomized,controlled clinical study was carried out. Fifty eight patients with FL were randomly divided into the group treated with silibinin capsules at dose of 70mg 3 times per day and the group treated with polyunsaturated phosphatidylcholine （PPC） 456mg 3 times per day. The therapeutic efficacies were evaluated by improvement in serum enzymes and blood fat. Results A significant improvement of serum enzyme and blood fat after treatment were found in the two groups （P〈0.05）. The severity of fatty liver improved obviously in the two groups after treatment by CT scan. Conclusions Silibinin capsule is as effective and safe as polyunsaturated phosphatidylcholine for improvement of liver function,and decreased blood fat in patients with FL.